Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders

Biological Psychiatry

Volumn 51, Issue 3, 2002, Pages 253-260

  Obrocea, Gabriela V ^a   Dunn, Robert M ^b   Frye, Mark A ^c   Ketter, Terence A ^d   Luckenbaugh, David A ^a   Leverich, Gabriele S ^a   Speer, Andrew M ^a   Osuch, Elizabeth A ^e   Jajodia, Kamal ^a   Post, Robert M ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

Affective disorders; Anticonvulsants; Gabapentin; Lamotrigine; Monotherapy; Predictors

Indexed keywords

CARBAMAZEPINE; GABAPENTIN; LAMOTRIGINE; PLACEBO; VALPROIC ACID;

ADULT; AFFECTIVE NEUROSIS; AGE DISTRIBUTION; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HOSPITALIZATION; HUMAN; LINEAR REGRESSION ANALYSIS; MALE; MANIC DEPRESSIVE PSYCHOSIS; MONOTHERAPY; MOOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE;

ACETIC ACIDS; ADULT; AGED; AMINES; ANTIDEPRESSIVE AGENTS; CROSS-OVER STUDIES; CROSS-SECTIONAL STUDIES; CYCLOHEXANECARBOXYLIC ACIDS; DOUBLE-BLIND METHOD; DRUG RESISTANCE; FEMALE; FORECASTING; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; MOOD DISORDERS; RECURRENCE; RETROSPECTIVE STUDIES; TRIAZINES;

EID: 0036468685     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(01)01206-9     Document Type: Article

References (80)

1. Gabapentin in the acute treatment of refractory bipolar disorder
2. Effects of gabapentin on the different components of peripheral and central neuropathic pain syndromes: A pilot study
3. Predictors of response to divalproex and lithium
4. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group
5. Methods for reliable longitudinal observation of behavior
6. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group
7. Predictors of response to mood stabilizers
8. Antidepressant effects of lamotrigine in rapid cycling bipolar disorder
9. Rapid cycling bipolar disorder and its treatment with valproate
10. Clinical studies on the use of lamotrigine in bipolar disorder
11. A double-blind placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group
12. A medication algorithm for treatment of bipolar rapid cycling?
13. Predictors of valproate response in bipolar rapid cycling
14. Gabapentin and motor fluctuations in Parkinson's disease
15. Morbidity in 202 patients followed for one year in the Stanley Foundation Bipolar Network (SFBN)
16. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder
17. Clinical factors in lithium carbonate prophylaxis failure
18. An open label study of gabapentin in the treatment of acute mania
19. Episode sequence in bipolar disorder and response to lithium treatment
20. Changes in the gene expression of GABAA receptor subunit mRNAs in the septum of rats subjected to pentylenetetrazol-induced kindling
21. A placebo controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders
22. Report on efficacy of treatments for bipolar disorder
23. Gabapentin treatment of mood disorders: A preliminary study
24. A randomized placebo-controlled comparative trial of gabapentin and propranolol in essential tremor
25. Unanswered questions, unknown future for one of our oldest medications
26. Treatment guidelines: Current and future management of bipolar disorder
27. GABA-stimulated chloride uptake during avian CNS development: Modulation by neurosteroids
28. Lithium vs carbamazepine in the maintenance treatment of schizoaffective disorder: A randomised study
29. A rating scale for depression
30. Sources of lithium resistance in mixed mania
31. Carbamazepine inhibition of N-Methyl-D-aspartate-evoked calcium influx in rat cerebellar granule cells
32. Predictors of recurrence in affective disorders - Analysis accounting for individual heterogeneity
33. Gender differences in treatment response to sertraline versus imipramine in chronic depression
34. Clinical experience using gabapentin adjunctively in patients with a history of mania or hypomania
35. Tolerance to the anticonvulsant effects of lamotrigine on amygdala kindled seizures: Cross-tolerance to carbamazepine but not valproate or diazepam
36. A double-blind, placebo-controlled study supporting the efficacy of lamotrigine (Lamictal) in unipolar depression
37. Life charting the course of bipolar disorder
38. Life charting of affective disorders
39. Absence seizures and carbamazepine in adults
40. A new twist for stopping the shakes? Revisiting GABAergic therapy for essential tremor
41. Pharmacologic agents for the treatment of acute bipolar mania
42. Sodium valproate: Its use in primary psychiatric disorders
43. Valproate in the treatment of bipolar disorder: Literature review and clinical guidelines
44. A pilot trial of adjunctive gabapentin in the treatment of bipolar disorder
45. Gabapentin for treatment of pain and tremor: A large case series
46. Outcome of bipolar disorder on long-term treatment with lithium
47. Effects of carbamazepine and lithium on affective disorders
48. Gabapentin for parkinsonism: A double-blind, placebo-controlled, crossover trial
49. Double-blind controlled trial of gabapentin in essential tremor
50. Gabapentin in bipolar disorder. A placebo-controlled trial of adjunctive therapy
51. Treatment of social phobia with gabapentin: A placebo-controlled study
52. Inappropriate use of carbamazepine and vigabatrin in typical absence seizures
53. Clinical experience using adjunctive gabapentin in treatment-resistant bipolar mixed states
54. Gabapentin as a potential treatment for anxiety disorders
55. Mood disorders: Treatment of bipolar disorders
56. Beyond lithium in the treatment of bipolar illness
57. Lithium tolerance and discontinuation as pathways to refractoriness
58. Antidepressant effects of carbamazepine
59. Lithium, carbamazepine, and valproate in affective illness. Biochemical and neurobiological mechanisms
60. Somatic recording of GABAergic autoreceptor current in cerebellar stellate and basket cells
61. Gabapentin for the treatment of postherpetic neuralgia: A randomized controlled trial
62. Bipolar disorder therapeutics: Maintenance treatment
63. Use of placebo control groups in evaluating efficacy of treatment of unipolar major depression
64. Gabapentin as an adjunct to standard mood stabilizers in outpatients with mixed bipolar symptomatology
65. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): The CGI-BP
66. Lamotrigine inhibits Ca2+ currents in cortical neurons: Functional implications
67. Sex and age differences of neurons expressing GABA-immunoreactivity in the rat bed nucleus of the stria terminalis
68. Differential effect of number of previous episodes of affective disorder on response to lithium or divalproex in acute mania
69. Depression during mania. Treatment response to lithium or divalproex
70. A summary of mechanistic hypotheses of gabapentin pharmacology
71. Bipolar depression: Pharmacotherapy and related therapeutic strategies
72. Inhibition of N-type calcium currents by lamotrigine in rat amygdalar neurones
73. Lamotrigine inhibits depolarization-evoked Ca++ influx in dissociated amygdala neurons
74. Cellular and molecular actions of lamotrigine: Possible mechanisms of efficacy in bipolar disorder
75. A rating scale for mania: Reliability, validity and sensitivity
76. Gabapentin as an adjunctive treatment in bipolar disorder
77. Clinical predictors of acute response with olanzapine in psychotic mood disorders